AzTrials
AzTrials

ComaARISENCT06617377

Combined Whole-brain Structural and Functional MRI for the Prediction of Neurological Recovery After Cardiac Arrest

A study testing advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan in people with Coma and Cardiac Arrest, run by University Hospital, Toulouse at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

To assess the performance of a predictive model resulting from the analysis of sMRI/fMRI/contrast-enhanced MRI-derived personalized connectomic data, as compared with standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) collected ≥ 72h from sedation withdrawal and in… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coma, Cardiac Arrest, Disorder of Consciousness
What is being tested?
advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
263 participants
Where
1 siteFrance
Study dates
16 Mar 2026to Sep 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients (male or female ≥ 18 years).
  • Coma, as indicated by a Glasgow Coma Scale (GCS) ≤ 8 (motor score ≤ 2) immediately after CA resuscitation and before sedation onset.
  • Persisting unconsciousness, defined as the inability to obey verbal commands, after at least 72 hours from complete withdrawal of sedation in normothermia conditions.
  • Written informed consent from patient's legal representative.
  • Affiliation or beneficiary to the French social security system.

Who cannot join

  • Brain death.
  • Coma explained by other cause than CA.
  • Likely poor neurological outcome based on early predictors, following ERC-ESCIM 2021 recommendations. In a comatose patient with GCS motor score ≤ 3 at ≥ 72 h from ROSC, in the absence of confounders, the identification of at least two of the following: bilaterally absent pupillary light and corneal reflexes at ≥ 72h, bilaterally absent N20 SSEP ≥ 24h; neuron-specific enolase (NSE) > 60 μg/l at 48h and/or 72h, status myoclonus ≤72h.
  • Decision of WLST previous to patient recruitment, based on early predictors of poor neurological outcome, age, co-morbidity, general organ function and patient's preferences.
  • Life expectancy shorter than 6 months based on pre-morbid conditions.
  • Former neurological functional disability (mRS > 2 before CA).
Show all 12Show fewer
  • MRI contraindication: medical material not MRI compatible, claustrophobia
  • Known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium
  • Severe kidney failure defined as a KDIGO score > 3 (glomerular filtration rate < 30 ml/min/1.73 m2 or renal replacement therapy).
  • Hemodynamic shock or severe respiratory failure precluding patient's transport and MRI scanning.
  • Pregnancy or nursing woman.
  • Patient under juridical protection.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • UHToulouse

    Toulouse

    Stein SILVA, PU-PH

    Recruiting

Other trials in France

About this study

Official title: Use of Brain Structural and Functional Connectomes for the Prediction of Neurological Recovery in Coma Patients After Cardiac Arrest

To assess the performance of a predictive model resulting from the analysis of sMRI/fMRI/contrast-enhanced MRI-derived personalized connectomic data, as compared with standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict anoxoischemic coma neurological outcome at 6 months.

Read the detailed description

There is a major need for timely, reliable and generalizable methods to predict outcomes in anoxo-ischemic coma patients. Standard predictors of poor outcome after cardiac arrest (CA) include clinical, electrophysiological and serum biomarkers data. All have substantial limitations in terms of reliability and generalizability. By providing whole-brain structural and functional connectivity maps, or connectomes, advanced MRI techniques have precisely revealed the brain network damages induced by CA. Because these individualized connectomic profiles contains critical information about consciousness recovery potential after CA, it can be hypothesized that these whole-brain quantitative data can be used to elaborate highly performant predictive algorithms for anoxo-ischemic coma patients.

Regarding advanced structural MRI (sMRI), two recent studies, including one from the investigators group, have shown a high sensitivity and specificity of these advanced techniques (diffusion tensor imaging -DTI; voxel-based morphometry -VBM) for predicting poor neurological recovery in anoxo-ischemic patients. However, these two studies collected data using poorly defined time window for MRI, across lengthy data collection periods (> 8 years) and did not apply a strict protocol of withdrawal or limitation-of-care decision to control from misclassification of outcome due to so-called selffulfilling prophecies. Concerning functional MRI (fMRI), a recent study from the investigators group reports that the strength of frontoparietal functional connectivity differs between anoxo-ischemic coma patients who recover and those who eventually score an unfavorable outcome at 3 months.

Furthermore, converging evidence suggest that task-based fMRI can be used to detect active, command-following modulation of cortical activity and, hence, consciousness in behaviorally unresponsive patients. This task-based fMRI pattern named Cognitive Motor Dissociation (CMD) show promise of radically improving good outcome neuroprognostication after CA. Finally, aiming to maximize the performance of MRI-derived predictive models, the investigators group have recently reported in a " proof-of-concept " study that a combined sMRI/fMRI connectomes and contrast-enhanced MRI data analysis, synergistically outperform alternative predictive models based on sMRI or fMRI data in isolation.

As recommended in recent guidelines for the management of anoxo-ischemic coma patients[7-9], a standard multimodal prognostication procedure will be followed, including the collection of standard predictors after at least 72h from complete withdrawal of sedation in normothermia condition: i) clinical examination and behavioral data (Day 1, 3 and 7 after inclusion): Glasgow Coma Scale - GCS, Full Outline of UnResponsiveness - FOUR, Coma Recovery Scale Revised - CRSR; and standardized brainstem reflex testing (FOUR, Glasgow-Liège score); ii) severity stratification scoring (Day 1 after inclusion): Cardiac Arrest Hospital Prognosis - CAHP, Out-of-Hospital Cardiac Arrest - OHCA, iii) laboratory findings (Day 1, 3 and 7 after inclusion) : NSE blood level (Day 1); iv) electrophysiological assessments: standard EEG using ACNS classification (once between Day 1 and Day 15 after inclusion); v) standard neuroimaging (once between Day 1 and Day 15 after inclusion): standard brain CT or MRI data (T1, T2*, SWI, DWI, FLAIR).

In addition to standard clinical neuroprognostication procedure, an advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).

sMRI/fMRI/ contrast-enhanced MRI data will be collected during the same scanning plot that will be used for standard MRI (T1, T2*, SWI, DWI, FLAIR) will encompass (total acquisition time = 45 min for all centers, except for Toulouse center = 60 min):

  • Structural MRI (total acquisition time = 30 min): i) gray matter: 3D T1-weithed data will be computed to assess whole brain cortical thickness and deep gray matter quantitative volumetry, ii) white matter, whole-brain DTI will be acquired to measure whole brain with matter fractional anisotropy (WWM-FA) and mean average diffusion coefficient (WB-aDC). A normalization procedure will be applied (healthy controls data from each neuroimaging facility).
  • Functional MRI (total acquisition time = 10 min for all centers, except for Toulouse center = 25 min): i) passive-task: multislice T2*-weighted for resting-state fMRI analysis images, acquisition time = 10 min; ii) active tasks: fMRI will be used to probe for volitional thought without selfexpression output (motor imagery and motor action), acquisition time = 15 min (only for Toulouse center).
  • Contrast-enhanced MRI (acquisition time = 5 min) for blood-brain barrier permeability assessment. As exploratory goals and seeking to: i) study the potential changes over time of advanced brain sMRI/fMRI/contrast-enhanced MRI data, a second identical advanced sMRI/fMRI/contrastenhanced MRI will be performed minimum 7 days (with an allowance of + 3 days) after the first MRI assessment in patients enrolled in Toulouse center (N = 30); ii) To investigate the usefulness for patient's neuroprognostication of novel brain injury fluid-derived biomarkers (ref), three peripheral blood samples will be collected two times (each sample blood volume= 5 ml), a first one immediately at patient's inclusion and second one 7 days later (N = 30, only for Toulouse center).

To gauge the clinical significance of this findings, the investigators plan to use largely validated neurological functional score (mRS, CPCs). Additionally, the investigator plan to explore as secondary evaluation criteria patients' level of consciousness (CRS-R) and the restauration of the pre-arrest health-related quality of life (HRQOL). These assessments will be performed at hospital discharge (mRS, CPC) and at 3 (mRS, CPC) and 6 months (mRS, CPC, CRS-R, HRQOL) after CA by specifically trained investigators, during the planned follow-up visit. Patient's medical care will be not be influenced by patient's study participation because the treating teams will be fully blinded to advanced sMRI/fMRI/contrast-enhanced MRI data (Figure 3). Patient's management will be performed in agreement with international guidelines. A strict and homogenous WLST protocol will be used in all the recruiting centers.

Being tested
advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan
Keywords
prognosis, coma, cardiac arrest, Structural MRI, resting-state, cognitive motor dissociation
Medical subject headings
Coma, Heart Arrest, Consciousness Disorders, Nervous System Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scanOther

    advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).

Study groups in NCT06617377
Study groupRoleWhat they receive
anoxo-ischemic coma patientsExperimentalStandard multimodal prognostication procedure will be followed, including the collection of standard predictors: i) clinical examination and behavioral data (Day 1, 3 and 7 after inclusion): Glasgow Coma Scale - GCS, Full Outline of UnResponsiveness - FOUR,Coma Recovery Scale Revised - CRS-R; and standardized brainstem reflex testing (FOUR, Glasgow-Liège score); ii) severity stratification scoring (Day 1 after inclusion): Cardiac Arrest Hospital Prognosis - CAHP, Out-of-Hospital Cardiac Arrest - OHCA, iii) laboratory findings (Day 1) : NSE blood level iv) electrophysiological assessments (once between Day 1 and Day 15 after inclusion): standard EEG following current guidelines and using ACNS classification; v) standard neuroimaging (once between Day 1 and Day 15 after inclusion): standard brain CT or MRI data (T1, T2*, SWI, DWI, FLAIR). An advanced wholebrain sMRI/fMRI/contrast-enhanced MRI scan will be acquired (between Day 1 and Day 7 after inclusion).
Receives: Other: advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. performance of a predictive model to predict 6 months neurological outcome

    Comparison between the area under the Receiver Operating Characteristic (ROC) curves of outcomes prediction models, based on either MRI-derived indicators (structural, functional and contrast-enhanced MRI), or built upon standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) both collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict 6 months neurological outcome as measured by the dichotomized Rankin Scale (mRS).

    Measured: month 6

Secondary outcomes (2)
  1. Performance of a predictive model to predict neurological outcome at hospital discharge

    Comparison between the area under the Receiver Operating Characteristic (ROC) curves of outcomes prediction models, based on either MRI-derived indicators (structural, functional and contrast-enhanced MRI) or built upon standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) both collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict neurological outcome at hospital discharge after CA by the dichotomized Rankin Scale (mRS).

    Measured: Hospital discharge

  2. Performance of a predictive model to predict neurological outcome at 3 months after CA

    Comparison between the area under the Receiver Operating Characteristic (ROC) curves of outcomes prediction models, based on either MRI-derived indicators (structural, functional and contrast-enhanced MRI) or built upon standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) both collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict neurological outcome at 3 months after CA by the dichotomized Rankin Scale (mRS).

    Measured: month 3

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Sep 2024
  2. Study start16 Mar 2026
  3. Primary completionSep 2029 (estimated)
  4. Study completionSep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
anoxo-ischemic coma patients
Masking
None (open label)
Enrolment
263 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06617377
Sponsor's protocol ID
RC31/22/0259
Other IDs
N° ID-RCB
Acronym
ARISE
Status last verified
Jun 2026
First submitted
24 Sep 2024
Last updated
29 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan in people with Coma and Cardiac Arrest, run by University Hospital, Toulouse at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Stein SILVA, MD PhD (0561772288 ext. +33, silva.s@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

performance of a predictive model to predict 6 months neurological outcome (time frame: month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in